Background: There have been sporadic reports of hypersensitivity reactions to plants of the Cannabinaceae family (hemp and hops), but it has remained unclear whether these reactions are immunologic or nonimmunologic in nature. Objective: We examined the IgE-binding and histamine-releasing properties of hashish and marijuana extracts by CAP-FEIA and a basophil histamine release test. Methods: Two workers at a forensic laboratory suffered from nasal congestion, rhinitis, sneezing and asthmatic symptoms upon occupational contact with hashish or marijuana, which they had handled frequently for 25 and 16 years, respectively. Neither patient had a history of atopic disease. Serum was analyzed for specific IgE antibodies to hashish or marijuana extract by research prototype ImmunoCAP, and histamine release from basophils upon exposure to hashish or marijuana extracts was assessed. Results were matched to those of 4 nonatopic and 10 atopic control subjects with no known history of recreational or occupational exposure to marijuana or hashish. Results: Patient 1 had specific IgE to both hashish and marijuana (CAP class 2), and patient 2 to marijuana only (CAP class 2). Controls proved negative for specific IgE except for 2 atopic individuals with CAP class 1 to marijuana and 1 other atopic individual with CAP class 1 to hashish. Stimulation of basophils with hashish or marijuana extracts elicited histamine release from basophils of both patients and 4 atopic control subjects. Conclusions: Our results suggest an IgE-related pathomechanism for hypersensitivity reactions to marijuana or hashish.

1.
Brown DT (ed): Cannabis. The Genus Cannabis, vol. 4. Amsterdam, Harwood Academic Publishers, 1998, p 272.
2.
Stadtmauer G, Beyer K, Bardina L, Sicherer SH: Anaphylaxis to ingestion of hempseed (Cannabis sativa). J Allergy Clin Immunol 2003;112:216–217.
3.
Stockli SS, Bircher AJ: Generalized pruritus in a patient sensitized to tobacco and cannabis. J Dtsch Dermatol Ges 2007;5:303–304.
4.
Stokes JR, Hartel R, Ford LB, Casale TB: Cannabis (hemp) positive skin tests and respiratory symptoms. Ann Allergy Asthma Immunol 2000;85:238–240.
5.
de Larramendi CH, Carnes J, Garcia-Abujeta JL, Garcia-Endrino A, Munoz-Palomino E, Huertas AJ, Fernandez-Caldas E, Ferrer A: Sensitization and allergy to Cannabis sativa leaves in a population of tomato (Lycopersicon esculentum)- sensitized patients. Int Arch Allergy Immunol 2008;146:195–202.
6.
Lindemayr H, Jager S: Beruflich erworbene Typ I-Allergie durch Hanfpollen und Haschisch. Derm Beruf Umwelt 1980;28:17–19.
7.
Majmudar V, Azam NA, Finch T: Contact urticaria to Cannabis sativa. Contact Dermatitis 2006;54:127.
8.
Mayoral M, Calderon H, Cano R, Lombardero M: Allergic rhinoconjunctivitis caused by Cannabis sativa pollen. J Investig Allergol Clin Immunol 2008;18:73–74.
9.
Perez JA Jr: Allergic reaction associated with intravenous marijuana use. J Emerg Med 2000;18:260–261.
10.
Vidal C, Fuente R, Iglesias A, Saez A: Bronchial asthma due to Cannabis sativa seed. Allergy 1991;46:647–649.
11.
Williams C, Thompstone J, Wilkinson M: Work-related contact urticaria to Cannabis sativa. Contact Dermatitis 2008;58:62–63.
12.
Eberlein-Konig B, Michel G, Ruzicka T, Przybilla B: Modulation of histamine release in vitro by fk506 and interleukin-3 is determined by sequence of incubation. Arch Dermatol Res 1997;289:606–608.
13.
Anibarro B, Fontela JL: Allergy to marihuana. Allergy 1996;51:200–201.
14.
Singh AB, Kumar P: Aeroallergens in clinical practice of allergy in India. An overview. Ann Agric Environ Med 2003;10:131–136.
15.
Freeman GL: Allergic skin test reactivity to marijuana in the Southwest. West J Med 1983;138:829–831.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.